ALNFL.PA NFL Biosciences SAS
- Market cap
- EUR 4.36M
- P/E
- -
- P/B
- 21.94x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALNFL.PA undervalued?
Graham numberThe Graham number of NFL Biosciences SAS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NFL Biosciences SAS fundamental analysis
1 of 11 checks passedROE 0/2
Negative ROE (-118.29%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-108.13%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 0/2
The stock's high Price-to-Book Value (P/BV) ratio (10.11x) suggests it's overvalued, potentially making it an expensive investment.
DER 2/2
The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.
Assets Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Graham Number 0/1
The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.
Dividend Growth 0/2
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.
Dividend 0/2
No dividends from the company in the past three years raises doubts about its profitability for shareholders.
Buffet Intrinsic Value 0/1
The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
NFL Biosciences SAS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NF…
Full company profileNFL Biosciences SAS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NFL Biosciences SAS annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 3.00 | 39.00 | 0.00 | 200K | 46.00 | 0.00 | - |
| Gross Profit | -254K | -169K | -531K | -2.24M | -56.1K | -67.1K | -2.52M | -186K |
| Operating Income | -347K | -318K | -902K | -3.01M | -4.43M | -2.79M | -3.87M | -7.95M |
| EBITDA | -304K | -271K | -1.08M | -2.81M | -4.05M | -2.65M | -3.76M | -7.77M |
| Net Income | -268K | -266K | -978K | -2.44M | -3.75M | -2.08M | -3.32M | -6.11M |
| EPS | -0.05 | -0.05 | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 | -0.48 |
| Balance Sheet | ||||||||
| Total Assets | 467K | 577K | 3.69M | 2.40M | 3.97M | 3.61M | 3.66M | 4.84M |
| Total Liabilities | 55.5K | 427K | 398K | 1.55M | 3.62M | 2.63M | 3.36M | 5.77M |
| Shareholders' Equity | 412K | 150K | 3.29M | 844K | 350K | 976K | 306K | -926K |
| Cash & Short-term Investments | 225K | 310K | 3.20M | 1.21M | 2.53M | 2.11M | 2.20M | 2.68M |
| Total Debt | - | 85.0K | 170K | 83.3K | 62.2K | 41.0K | 583K | 3.27M |
| Cash Flow | ||||||||
| Operating Cash Flow | - | 83.9K | 87.0K | 105K | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Free Cash Flow | - | 83.9K | 87.0K | 105K | - | - | - | - |
| Ratios | ||||||||
| ROE | -65.1% | -177.6% | -29.8% | -289.5% | -1,070.3% | -213.1% | -1,083.8% | - |
| ROA | -57.4% | -46.2% | -26.5% | -102.0% | -94.3% | -57.6% | -90.6% | -126.1% |
| Net Profit Margin | - | -8,882,866.7% | -2,508,317.9% | - | -1,872.6% | -4,523,563.0% | - | - |
| Debt to Equity | - | 0.57x | 0.05x | 0.10x | 0.18x | 0.04x | 1.90x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NFL Biosciences SAS dividends
NFL Biosciences SAS has not paid dividends in the last 7 fiscal years.
Who owns NFL Biosciences SAS
- Insiders 14.21%
- Institutions 0.00%
- Public & others 85.79%
- Shares outstanding 12.7M
- Free float 10.9M
NFL Biosciences SAS company profile
- Company name
- NFL Biosciences SAS
- Ticker
- ALNFL.PA
- ISIN
- FR0014003XT0
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 199 Rue HElEne Boucher, Castelnau-le-Lez, France, 34170
- Phone
- 33 4 11 93 76 67
- Website
- nflbiosciences.com
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
NFL Biosciences SAS management
5- Mr. Bruno Lafont M.B.A., M.Sc.Founder, CEO, MD & Chairman
- Mr. Guillaume AudemaChief Financial Officer
- Dr. Ignacio Faus M.B.A., Ph.D.Deputy MD & Director
- Dr. Yannick Pletan M.D., M.Sc.Chief Medical Officer & Director · born 1953
- Ms. Lara Babich Ph.D.Head of Development & Manufacturing